BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn

Transfusion Medicine

Volumn 24, Issue 1, 2014, Pages 8-20

  Qureshi, H ^a   Massey, E ^b   Kirwan, D ^c   Davies, T ^b   Robson, S ^d   White, J ^e   Jones, J ^f   Allard, S ^b  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c UNIVERSITY OF EXETER   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e WEST HERTFORDSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^f Welsh Blood Service   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RHESUS D ANTIBODY; BLOOD GROUP RHESUS SYSTEM; IMMUNOLOGIC FACTOR; RHO(D) ANTIGEN;

ARTICLE; BLEEDING; BLOOD TRANSFUSION; DRUG ADMINISTRATION; DRUG BIOAVAILABILITY; DRUG DOSE; DRUG SAFETY; FETOMATERNAL TRANSFUSION; FETUS DEATH; FETUS DISEASE; GESTATIONAL AGE; HEALTH CARE PERSONNEL; HEMOLYTIC ANEMIA; HUMAN; INFORMED CONSENT; LABORATORY TEST; NEWBORN DISEASE; PRACTICE GUIDELINE; PREGNANCY; PRENATAL CARE; THROMBOCYTE TRANSFUSION; BLOOD; BLOOD GROUP RHESUS SYSTEM; ERYTHROBLASTOSIS, FETAL; FEMALE; MALE; NEWBORN; THIRD TRIMESTER PREGNANCY;

ERYTHROBLASTOSIS, FETAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY TRIMESTER, THIRD; RH-HR BLOOD-GROUP SYSTEM; RHO(D) IMMUNE GLOBULIN;

EID: 84892659649     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/tme.12091     Document Type: Article

References (47)

1. Allam, J., Cox, M. & Yentis, S.M. (2008) Cell salvage in obstetrics. International Journal of Obstetric Anesthesia, 17, 37-45.
2. Bichler, J., Schöndorfer, G., Pabst, G. & Andresen, I. (2003) Pharmacokinetics of anti-D IgG in pregnant Rh D negative women. BJOG: An International Journal of Obstetrics and Gynaecology, 110, 39-45.
3. Bowman, J.M., Chown, B., Lewis, M. & Pollock, J.M. (1978) Rh-isoimmunization during pregnancy: antenatal prophylaxis. Canadian Medical Association Journal, 118, 623-627.
4. British Committee for Standards in Haematology (BCSH - b). (2003) Guidelines for the use of Platelet transfusions. British Journal of Haematology, 122, 10-23.
5. British Committee for Standards in Haematology (BCSH - c). (2007) Guidelines for blood grouping and red cell antibody testing in pregnancy. Transfusion Medicine, 17, 252-262.
6. British Committee for Standards in Haematology (BCSH - a). (2009) Guidelines for the estimation of fetomaternal haemorrhage. URL http://www.bcshguidelines.com/documents/BCSH_FMH_bcsh_sept2009.pdf (Accessed 3/12/2013).
7. Catling, S.J., William, S. & Fielding, A.M. (1999) Cell salvage in obstetrics: an evaluation of the ability of cell salvage combined with leucocyte depletion filtration to remove amniotic fluid from operative blood loss at caesarean section. International Journal of Obstetric Anesthesia, 8, 79-84.
8. Chilcott, J., Lloyd Jones, M., Wight, J., Wray, J., Beverley, C. & Tappenden, P. (2003) A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. Health Technology Assessment, 7, 1-72.
9. Clausen, F.B., Christiansen, M., Steffensen, R. et al. (2012) Report of the first nationally implemented clinical routine screening for fetal RHD in D-pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion, 52, 752-758.
10. Critical Appraisal Skills Program (CASP). (2004) Milton Keynes Primary Care NHS Trust. URL http://www.phru.nhs.uk/casp/reviews.htm (Accessed 22/9/2005).
11. Crowther, C.A. & Middleton, P. (1997) Anti-D administration after childbirth for preventing Rhesus alloimmunisation. Cochrane Database of Systematic Reviews, 2 Art. No.:CD000021. DOI:10.1002/14651858.CD000021.
12. Daniels, G., Finning, K., Martin, P. & Massey, E. (2009) Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenatal Diagnosis Journal, 29, 101-107.
13. Department of Health (DH). (1997) The new NHS, Modern Dependable White Paper. NHS, London.
14. Department of Health (DH). (1998) A first class service - quality in the new NHS. NHS, London.
15. Department of Health (DH). (2007) Health service circular HSC 2007/001, Better Blood Transfusion, Safe and Appropriate use of blood. URL http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_080803.pdf (Accessed 30/11/2010).
16. European Commission. (2000) Manufacture of medicinal products derived from human blood or plasma - Revision of Annexe 14 to the EU Guide to Good Manufacturing Practice.
17. Finning, K., Martin, P., Summers, J., Massey, E., Poole, G. & Daniels, G. (2008) Effect of high throughput RH D typing of fetal DNA in maternal plasma on use of anti-Rh D immunoglobulin in Rh D negative pregnant women: prospective feasibility study. British Medical Journal, 336, 816-818.
18. Fong, J., Gurewitsch, E.D., Kump, L. & Klein, R. (1999) Clearance of fetal products and subsequent immunoreactivity of blood salvaged at cesarean delivery. Journal of Obstetrics and Gynaecology, 93, 968-972.
19. Geifman-Holzman, O., Groegut, C.A. & Gaughan, J.P. (2006) Diagnostic accuracy of non invasive fetal Rh genotyping from maternal blood - a meta-analysis. American Journal of Obstetrics and Gynaecology, 195, 1163-1173.
20. Ghosh, S. & Murphy, W.G. (1994) Implementation of the rhesus prevention programme: a prospective study. Scottish Medical Journal, 39, 147-149.
21. Hartwell, E.A. (1998) Use of Rh immune globulin: ASCP Practice Parameter. American Society of Clinical Pathologists. American Journal of Clinical Pathology, 110, 281-292.
22. Huchet, J., Dallemagne, S., Huchet, C., Brossard, Y., Larsen, M. & Parnet-Mathieu, F. (1987) Ante-partum administration of preventive treatment of Rh-D immunisation in rhesus-negative women. Parallel evaluation of transplacental passage of fetal blood cells. Results of a multicentre study carried out in the Paris region. Journal de gynécologie, obstétrique et biologie de la reproduction, 16, 101-111.
23. Kumpel, B.M. (2006) On the immunologic basis of Rh immune globulin (anti-D) prophylaxis. Transfusion, 46, 1652-1656.
24. Lee, D., Contreras, M., Robson, S.C., Rodeck, C.H. & Whittle, M.J. (1999) Recommendations for the use of anti-D Ig immunoglobulin for Rh prophylaxis. Transfusion Medicine, 9, 93-97.
25. MacKenzie, I.Z., Bowell, P., Gregory, H., Pratt, G., Guest, C. & Entwistle, C.C. (1999) Routine antenatal rhesus D immunoglobulin prophylaxis: the results of a prospective 10year study. British Journal of Obstetrics and Gynaecology, 106, 492-497.
26. MacKenzie, I.Z., Bichler, J., Mason, G.C. et al. (2004) Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulin. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 117, 154-161.
27. MacKenzie, I.Z., Roseman, F., Findlay, J. et al. (2006) The Kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D immunoglobulin. British Journal of Obstetrics and Gynaecology, 113, 97-101.
28. Mayne, S., Parker, J.H., Harden, T.A., Dodds, S.D. & Beale, J.A. (1997) Rate of Rh D sensitisation before and after implementation of a community based antenatal prophylaxis programme. British Medical Journal, 315, 1588.
29. Menitove, J.E. (2002) Immunoprophylaxis for D negative patients receiving platelet transfusion from D negative donors. Transfusion, 42, 136-138.
30. Milkins, C., Berryman, J., Cantwell, C. et al. (2012) Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. Transfusion Medicine, 23, 3-35.
31. Mollison, P.L., Mollison, P.L., Engelfriet, C.P. & Contreras, M. (1997) Blood Transfusion in Clinical Medicine (10 edn), 318. Chichester, UK.
32. National Institute for Health and Clinical Excellence (NICE). (2002) Full guidance on the use of routine antenatal anti-D prophylaxis for Rh D negative women. Technology Appraisal Guidance No. 41.
33. National Institute for Health and Clinical Excellence (NICE). (2008) Routine antenatal anti-D prophylaxis for women who are rhesus D negative. URL http://www.nice.org.uk/nicemedia/pdf/TA156Guidance.pdf (Accessed 8/1/2011).
34. National Institute for Health and Clinical Excellence (NICE CG62). (2008) Antenatal Care, Routine care for the healthy pregnant woman. URL http://www.nice.org.uk/nicemedia/live/11947/40115/40115.pdf (Accessed 11/12/2010).
35. National Institute for Health and Clinical Excellence (NICE CG154). (2012) Ectopic pregnancy and miscarriage: Diagnosis and initial management in early pregnancy of ectopic pregnancy and miscarriage. URL http://www.publications.nice.org.uk/ectopic-pregnancy-and-miscarriage-cg154 (Accessed 13/03/2013).
36. Parker, J., Wray, J., Gooch, A., Robson, S. & Qureshi, H. (2013) Guidelines for the use of prophylactic anti-D immunoglobulin. URL http://www.bcshguidelines.com/documents/Anti-D_bcsh_07062006.pdf (Accessed 3/12/2013).
37. Pilgrim, H., Lloyd-Jones, M. & Rees, A. (2009) Routine antenatal anti-D prophylaxis for Rh D negative women: a systematic review and economic evaluation. Health Technology Assessment, 13, 1-126 .
38. Royal College of Obstetrics and Gynaecologists (RCOG Green Top Guideline 38 February). (2010) The management of gestational trophoblastic disease. URL http://www.rcog.org.uk/files/rcog-corp/GT38ManagementGestational0210.pdf (Accessed 3/12/2013).
39. Royal College of Obstetrics and Gynaecologists (RCOG Green Top Guideline 22, revised March). (2011) The Use of Anti-D Immunoglobulin for Rhesus D Prophylaxis. URL http://www.rcog.org.uk/files/rcog-corp/GTG22AntiD.pdf (Accessed 3/12/2013).
40. Smith, G.N., Griffiths, B., Mollison, D. & Mollison, P.L. (1972) Uptake of IgG after intramuscular and subcutaneous injection. The Lancet, 299, 1208-1212.
41. Tovey, L.A.D. (1992) Towards the conquest of Rh haemolytic disease: Britain's contribution and the role of serendipity. Transfusion Medicine, 2, 99-109.
42. Tovey, L.A.D., Townley, A., Stevenson, B.J. & Taverner, J. (1983a) The Yorkshire antenatal anti-D trial in primigravidae. The Lancet, 2, 244-246.
43. Tovey, L.A., Townley, A., Stevenson, B.J. & Taverner, J. (1983b) The Yorkshire antenatal anti-D immunoglobulin trial in primigravidae. The Lancet, 2, 244-246.
44. Trolle, B. (1989) Prenatal Rh-immune prophylaxis with 300 micrograms immune globulin anti-D in the 28th week of pregnancy. Acta Obstetricia et Gynecologica Scandinavica, 68, 45-47.
45. Urbaniak, S.J. & Greiss, M.A. (2000) Rh D haemolytic disease of the fetus and the newborn. Blood Reviews, 14, 44-61.
46. World Health Organisation. (1971) Technical Report Series No. 468. Prevention of Rh Sensitisation. Report of a WHO Scientific Group. URL http://whqlibdoc.who.int/trs/WHO_TRS_468.pdf (Accessed 11/11/2011).
47. Woelfer, B., Schuchter, K., Janisiw, M., Hafner, E., Philipp, K. & Panzer, S. (2004) Post delivery levels of anti-D IgG prophylaxis in D - mothers depend on maternal body weight. Transfusion, 44, 512-517.